Archive for April, 2015

Home »

AAPL: iPhone 6 Upgrades Setting up a Difficult Compare

Using data disclosed by Apple during its 2FQ 15 earnings release and call, it’s possible to triangulate iPhone mix and penetration of sales to existing users: with an average ASP of $659, we estimate iPhone 6/6 Plus represent 60-65% of

Read More

ABC/CAH/MCK: US Generic Inflation Continues in 1Q15

On a sales-weighted basis, prices (paid by retailers) for US generics rose 4.7% in 1Q15, substantially faster than in 4Q14 (0.5%), and on par with the average pace of inflation (5.1%) seen since early 2013 All else held equal, generic

Read More

ABBV/PCYC: Imbruvica and ABT-199 are Synergistic

ABBV’s acquisition of PCYC raised eyebrows, both because of the valuation placed on PCYC, and because ABBV has a promising lead compound (ABT-199) being developed for the same B-cell malignancies treated by PCYC’s main product (Imbruvica) Much debate centers on

Read More

Mobile Commerce: AAPL and GOOG Have Home Field Advantage

AAPL and GOOG have enormous advantages in the emerging phenomenon of mobile commerce. With platform control over mobile devices, they stand between consumers and the many companies looking to engage with them to influence and complete mobile transactions online and

Read More

SNY: The (multi-faceted) Bull Case

We believe SNY is undervalued, for 3 independent reasons, any one of which is sufficient to show the shares are undervalued With partner REGN, SNY is one of two entrants (the other being AMGN) in the emerging PCSK9 class. Our

Read More

CVS, MCK, RAD, WBA: How WBA or CVS can fight narrowing retail networks – buy RAD

US retail pharmacy dispensing margins have grown to a point at which forcing them lower is a priority for drug benefit designers. Because the US has roughly 34% more pharmacy outlets than it needs, this can be (and is being)

Read More